Hospitals may be discharging XDR-TB patients too soon – study

A paediatric TB patient. (Credit: The Global Fund to Fight AIDS, TB and Malaria)
Behind the headlines: Doctors caution that discharged XDR-TB patients are not behind the bulk of XDR-TB transmission in the country

Published online today in the medical journal, The Lancet, the research followed 107 XDR-TB patients from three hospitals Cape Town, Uppington and Johannesburg for five years. During the course of the study, about 40 percent of the patients were eventually discharged.

However, researchers found that of those who had been discharged, about 40 percent were not cured at the time they were sent home and a about third of these patients were at a high risk of transmitting the disease, according to the study conducted by the University of Cape Town (UCT), Stellenbosch University and the US Emory University School of Medicine.

The study is the first to suggest that South African hospitals may be discharging more XDR-TB patients before they are fully cured than previously thought, according to one of the researchers, Keertan Dheda, a professor at UCT’s department of medicine.

“Alarmingly, we have shown for the first time that… treatment failure, and discharge of such patients into the wider community, is occurring systematically on a country-wide level in South Africa,” said Dheda, who added that many hospitals feel pressure to discharge patients due to the scarce number of beds available. “We think (these findings) are a mirror of what is happening on a wider scale.”

Dheda and his team also recorded at least one instance in which a patient had transmitted the diseases to a relative. The patient and his brother both eventually died, as did almost two-thirds of all patients enrolled in the study.

XDR-TB is resistant to both of the most commonly used anti-TB drugs, isoniazid and rifampin, as well as at least one second-line drug. With a limited number of drugs available to treat the disease, patients who do not respond to treatment often run out of other options.

However, some doctors have caution that discharged XDR-TB patients are not the source of South Africa’s large XDR-TB problem.

Dr Gilles van Cutsem is the South African medical coordinator for international humanitarian organisation Medicines Sans Frontières (MSF). He says that people are much more likely to contract XDR-TB from people who have not been diagnosed and started treatment than they are from those who have been discharged from hospitals.

“Yes, some people are getting infected by people who have been discharged or are failing treatment but the majority of transmission doesn’t happen like that,” van Cutsem told Health-e. “The majority of transmission is by people who haven’t been diagnosed and started on treatment.”

Decentralisation a move in the right direction

Phumeza Tisile beat the odds and survived XDR-TB with help from community-based care that allowed her to be close to family and friends

What is clear from Dheda’s research is that government’s 2012 decision to decentralise the treatment of multidrug-resistant TB (MDR-TB) has been a step in the right direction. While resistant to fewer treatments than XDR-TB, MDR-TB is also resistant to isoniazid and rifampin.

“MDR-TB has been officially decentralised…that makes treatment much more accessible,” Dheda added. “The official policy is still to admit XDR-TB patients into facilities but with the sheer burden of disease it wont be long before that is also decentralised.”

In his Lancet article, Dheda and his co-authors advocate for the expansion of community-based, in-patient XDR-TB treatment centres that are linked with good home-based and palliative care services as an answer to South Africa’s shortage of beds. This approach has already been pioneered in the Western Cape by MSF, which recently handed its XDR-TB treatment centre – Lizo Nobanda – over to St Luke’s Hospice.

Located in Khayelitsha, Lizo Nobanda allowed XDR-TB patients to stay for months at the centre to complete or re-start treatment and get help dealing with the sometimes-crippling side effects of treatment.

Phumeza Tisile is one of the lucky ones. The former Lizo Nobanda patient was officially cured of XDR-TB in August after years of treatment.  She calls being cured “a miracle.”

“Imagine this – just a few months back you are told that you must prepare your soul for death because there is no way that you can survive and that the doctors have run out of options,” says Tisile of being cured. “Then a few weeks later they are singing a different tune… it is so exciting to be told you are no loner dying”

Tisile also spent time in Cape Town’s Brooklyn Chest Hospital and says that the move to Lizo Nobanda allowed her to be closer to her family – and made treatment feel like less of a prison.

“At Lizo Nobanda there were no visiting hours so visitors can stay as long as they wish, and the patients are free – we weren’t locked up in rooms like in the big hospitals,” she remembers.

“Even the nurses were not the same,” she adds.

Phumeza pull quote
“At the Brooklyn Chest Hospital, the nurses were just doing their jobs,” says Tisile, who contracted XDR-TB in her first year of varsity. “At Lizo Nobanda, they became like parents.”

While community-based care may not be cheaper than hospital admissions, the advantages to patients may be priceless, according to van Cutsem who says he thinks South Africa will see more treatment facilities like it in the future to help control the country’s XDR-TB epidemic.

While Lizo Nobanda was a standalone facility, other community-based approaches could include XDR-TB wards at district hospitals or an nonprofit-run hospice approach.

“We started Lizo Nobanda as part of the decentralisation programme because we wanted to look at treating patients as much as possible in their communities,” he said. “We need to establish more Lizo Nobanda-type facilities that provide community-based, in-patient facilities where patients can…be admitted for a longer time but in a more humane environment.” – Health-e News Service.



Free to Share

Creative Commons License

Republish our articles for free, online or in print, under a Creative Commons license.


Leave a Reply

Your email address will not be published. Required fields are marked *

Stay in the loop

We love that you love visiting our site. Our content is free, but to continue reading, please register.

Newsletter Subscription

Enable Notifications OK No thanks